TY - JOUR
T1 - Determinants of women's decision making on whether to treat nausea and vomiting of pregnancy pharmacologically
AU - Baggley, Anne
AU - Navioz, Yvette
AU - Maltepe, Caroline
AU - Koren, Gideon
AU - Einarson, Adrienne
N1 - Funding Information:
The Motherisk NVP Helpline is supported by Duchesnay, Inc., Laval, Quebec, Canada. Yvette Navioz is a counselor and researcher at the Motherisk NVP Helpline, The Hospital for Sick Children, Toronto. Caroline Maltepe, BA, is a counselor and researcher at The Motherisk NVP Helpline, The Hospital for Sick Children, Toronto, Canada. Gideon Koren, MD, FRCP, is the Director of The Motherisk Program, The Hospital for Sick Children and a Career Scientist at The Ministry of Health of Ontario. Adrienne Einarson, RN, is the Assistant Director, The Motherisk Program and project director in The Research Institute, The Hospital for Sick Children, Toronto, Canada.
PY - 2004/7
Y1 - 2004/7
N2 - Nausea and vomiting of pregnancy (NVP) affects up to 80% of all women to some degree during their pregnancies. Diclectin (doxylamine and pyridoxine [vitamin B6]) has been on the Canadian market for many years and is indicated as the drug of choice for the treatment of NVP. However, some women choose not to treat NVP with pharmacologic measures, perhaps due to a persistent fear of teratogenic risk. The objective of this study was to determine the factors that influence a woman's decision not to treat NVP with pharmacologic measures. Fifty-nine women recruited from the Motherisk Nausea and Vomiting Helpline completed a questionnaire. All were informed that Diclectin was considered safe for use during pregnancy. At a follow-up telephone call, 34% were not using any pharmacologic treatment, and of those who were taking the drug, 26% were using less than the recommended dose. Reasons cited for not using the medication were insufficient safety data, preference for non-pharmacologic methods, and being made to feel uncomfortable by the physician. Of the women who did use Diclectin, the most convincing reassuring information that it was safe to use came from friends and family. Many other factors play a large role in a women's decision making.
AB - Nausea and vomiting of pregnancy (NVP) affects up to 80% of all women to some degree during their pregnancies. Diclectin (doxylamine and pyridoxine [vitamin B6]) has been on the Canadian market for many years and is indicated as the drug of choice for the treatment of NVP. However, some women choose not to treat NVP with pharmacologic measures, perhaps due to a persistent fear of teratogenic risk. The objective of this study was to determine the factors that influence a woman's decision not to treat NVP with pharmacologic measures. Fifty-nine women recruited from the Motherisk Nausea and Vomiting Helpline completed a questionnaire. All were informed that Diclectin was considered safe for use during pregnancy. At a follow-up telephone call, 34% were not using any pharmacologic treatment, and of those who were taking the drug, 26% were using less than the recommended dose. Reasons cited for not using the medication were insufficient safety data, preference for non-pharmacologic methods, and being made to feel uncomfortable by the physician. Of the women who did use Diclectin, the most convincing reassuring information that it was safe to use came from friends and family. Many other factors play a large role in a women's decision making.
KW - Decision making
KW - Nausea and vomiting
KW - Pregnancy
KW - Treatment
UR - https://www.scopus.com/pages/publications/3242752797
U2 - 10.1016/j.jmwh.2004.03.011
DO - 10.1016/j.jmwh.2004.03.011
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 15236716
AN - SCOPUS:3242752797
SN - 1526-9523
VL - 49
SP - 350
EP - 354
JO - Journal of Midwifery and Women's Health
JF - Journal of Midwifery and Women's Health
IS - 4
ER -